Abeona Therapeutics Inc. (ABEO)
NASDAQ: ABEO · Real-Time Price · USD
6.84
-0.12 (-1.65%)
Sep 4, 2025, 3:16 PM - Market open
Abeona Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts that cover Abeona Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $18.17, which forecasts a 165.84% increase in the stock price over the next year. The lowest target is $15 and the highest is $20.
Price Target: $18.17 (+165.84%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Abeona Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 2 | 2 | 2 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +192.61% | Aug 18, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $19 → $20 | Buy | Maintains | $19 → $20 | +192.61% | Aug 15, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +192.61% | Jul 16, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +192.61% | Jul 14, 2025 |
| Oppenheimer | Oppenheimer | Buy Initiates $19 | Buy | Initiates | $19 | +177.98% | Jun 2, 2025 |
Financial Forecast
Revenue This Year
27.07M
Revenue Next Year
119.02M
from 27.07M
Increased by 339.63%
EPS This Year
-0.10
from -1.55
EPS Next Year
0.12
from -0.10
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 33.6M | 147.3M | |||
| Avg | 27.1M | 119.0M | |||
| Low | 16.1M | 94.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 444.2% | |||
| Avg | - | 339.6% | |||
| Low | - | 247.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.05 | 0.91 | |||
| Avg | -0.10 | 0.12 | |||
| Low | -1.01 | -0.46 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.